Not a comparison of the valves you are considering, but there's a very good explanation of the history the clinical development of the Inspiris Resilia valve here...
www.edwards.com
The ongoing study, called the Resilience study, started in 2018 with 250 patients who received the valve under 65 years old.
"The objective of the RESILIENCE trial is to determine the time to valve failure due to valve deterioration requiring re-intervention, as well as to collect/investigate early potential predictors of valve durability (e.g. calcification and hemodynamic deterioration) in RESILIA tissue. The RESILIENCE trial is the first prospective study to associate both clinical and imaging definitions of SVD with long-term (11 years) bioprosthetic valve durability."
I believe there are no negative signals coming from this or any of the previous studies...i.e. "so far so good ". It will run to 11 years post op in these patients.
It may be the costliest, but if it provides longer life with less probability of a future SAVR, then it's a very attractive solution for people considering tissue valves.